Recommended Topic Related To:

Selzentry

"Increasing HIV prevention and treatment options make it more important than ever to get tested and know your status.

September 27 is National Gay Men's HIV/AIDS Awareness Day, a time to reflect on the heavy toll of HIV among gay and bis"...

Selzentry

Selzentry

SIDE EFFECTS

The following adverse reactions are discussed in other sections of the labeling:

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Trials in Treatment-Experienced Subjects

The safety profile of SELZENTRY is primarily based on 840 HIV-1-infected subjects who received at least 1 dose of SELZENTRY during two Phase 3 trials. A total of 426 of these subjects received the indicated twice-daily dosing regimen.

Assessment of treatment-emergent adverse events is based on the pooled data from 2 trials in subjects with CCR5-tropic HIV-1 (A4001027 and A4001028). The median duration of therapy with SELZENTRY for subjects in these trials was 48 weeks, with the total exposure on SELZENTRY twice daily at 309 patient-years versus 111 patient-years on placebo + optimized background therapy (OBT). The population was 89% male and 84% white, with mean age of 46 years (range: 17 to 75 years). Subjects received dose equivalents of 300 mg maraviroc once or twice daily.

The most common adverse events reported with twice-daily therapy with SELZENTRY with frequency rates higher than placebo, regardless of causality, were upper respiratory tract infections, cough, pyrexia, rash, and dizziness. Additional adverse events that occurred with once-daily dosing at a higher rate than both placebo and twice-daily dosing were diarrhea, edema, influenza, esophageal candidiasis, sleep disorders, rhinitis, parasomnias, and urinary abnormalities. In these 2 trials, the rate of discontinuation due to adverse events was 5% for subjects who received SELZENTRY twice daily + OBT as well as those who received placebo + OBT. Most of the adverse events reported were judged to be mild to moderate in severity. The data described below occurred with twice-daily dosing of SELZENTRY.

The total number of subjects reporting infections were 233 (55%) and 84 (40%) in the group receiving SELZENTRY twice daily and the placebo group, respectively. Correcting for the longer duration of exposure on SELZENTRY compared with placebo, the exposure-adjusted frequency (rate per 100 subject-years) of these events was 133 for both SELZENTRY twice daily and placebo.

Dizziness or postural dizziness occurred in 8% of subjects on either SELZENTRY or placebo, with 2 subjects (0.5%) on SELZENTRY permanently discontinuing therapy (1 due to syncope, 1 due to orthostatic hypotension) versus 1 subject on placebo (0.5%) permanently discontinuing therapy due to dizziness.

Treatment-emergent adverse events, regardless of causality, from A4001027 and A4001028 are summarized in Table 3. Selected events occurring at ≥ 2% of subjects and at a numerically higher rate in subjects treated with SELZENTRY are included; events that occurred at the same or higher rate on placebo are not displayed.

Table 3: Percentage of Subjects With Selected Treatment-Emergent Adverse Events (All Causality) ≥ 2% on SELZENTRY (and at a higher rate compared with placebo) Trials A4001027 and A4001028 (Pooled Analysis, 48 Weeks) NR = Not recommended.

Body System/ Adverse Event SELZENTRY Twice Dailya Placebo
N = 426 (%) Exposure-adjusted rate (per 100 ptyrs)
PYE = 309b
N = 209 (%) Exposure-adjusted rate (per 100 ptyrs)
PYE = 111b
Eye Disorders
  Conjunctivitis 2 3 1 3
  Ocular infections, inflammations, and associated manifestations 2 3 1 2
Gastrointestinal Disorders
  Constipation 6 9 3 6
General Disorders and Administration Site Conditions
  Pyrexia 13 20 9 17
  Pain and discomfort 4 5 3 5
Infections and Infestations
  Upper respiratory tract infection 23 37 13 27
  Herpes infection 8 11 4 8
  Sinusitis 7 10 3 6
  Bronchitis 7 9 5 9
  Folliculitis 4 5 2 4
  Pneumonia 2 3 5 10
  Anogenital warts 2 3 1 3
  Influenza 2 3 0.5 1
  Otitis media 2 3 0.5 1
Metabolism and Nutrition Disorders
  Appetite disorders 8 11 7 13
Musculoskeletal and Connective Tissue Disorders
  Joint-related signs and symptoms 7 10 3 5
  Muscle pains 3 4 0.5 1
Neoplasms Benign, Malignant, and Unspecified
  Skin neoplasms benign 3 4 1 3
Nervous System Disorders
  Dizziness/postural dizziness 9 13 8 17
  Paresthesias and dysesthesias 5 7 3 6
  Sensory abnormalities 4 6 1 3
  Disturbances in consciousness 4 5 3 6
  Peripheral neuropathies 4 5 3 6
Psychiatric Disorders
  Disturbances in initiating and maintaining sleep 8 11 5 10
  Depressive disorders 4 6 3 5
  Anxiety symptoms 4 5 3 7
Renal and Urinary Disorders
  Bladder and urethral symptoms 5 7 1 3
  Urinary tract signs and symptoms 3 4 1 3
Respiratory, Thoracic, and Mediastinal Disorders
  Coughing and associated symptoms 14 21 5 10
  Upper respiratory tract signs and symptoms 6 9 3 6
  Nasal congestion and inflammations 4 6 3 5
  Breathing abnormalities 4 5 2 5
  Paranasal sinus disorders 3 4 0.5 1
Skin and Subcutaneous Tissue Disorders
  Rash 11 16 5 11
  Apocrine and eccrine gland disorders 5 7 4 7.5
  Pruritus 4 5 2 4
  Lipodystrophies 3 5 0.5 1
  Erythemas 2 3 1 2
Vascular Disorders
  Vascular hypertensive disorders 3 4 2 4
a300-mg dose equivalent.
bPYE = Patient-years of exposure.

Laboratory Abnormalities

Table 4 shows the treatment-emergent Grade 3-4 laboratory abnormalities that occurred in > 2% of subjects receiving SELZENTRY.

Table 4: Maximum Shift in Laboratory Test Values (Without Regard to Baseline) Incidence ≥ 2% of Grade 3-4 Abnormalities (ACTG Criteria) Trials A4001027 and A4001028 (Pooled Analysis, 48 Weeks)

Laboratory Parameter Preferred Term Limit SELZENTRY Twice Daily + OBT
(N = 421)a %
Placebo + OBT
(N = 207)a %
Aspartate aminotransferase > 5.0 x ULN 4.8 2.9
Alanine aminotransferase > 5.0 x ULN 2.6 3.4
Total bilirubin > 2.5 x ULN 5.5 5.3
Amylase > 2.0 x ULN 5.7 5.8
Lipase > 2.0 x ULN 4.9 6.3
Absolute neutrophil count < 750/mm³ 4.3 2.4
aPercentages based on total subjects evaluated for each laboratory parameter.
ULN=upper limit of normal.

Trial in Treatment-Naive Subjects

Treatment-Emergent Adverse Events: Treatment-emergent adverse events, regardless of causality, from Trial A4001026, a double-blind, comparative, controlled trial in which 721 treatment-naive subjects received SELZENTRY 300 mg twice daily (N = 360) or efavirenz (N = 361) in combination with zidovudine/lamivudine for 96 weeks, are summarized in Table 5. Selected events occurring in ≥ 2% of subjects and at a numerically higher rate in subjects treated with SELZENTRY are included; events that occurred at the same or higher rate on efavirenz are not displayed.

Table 5: Percentage of Subjects With Selected Treatment-Emergent Adverse Events (All Causality) ( ≥ 2% on SELZENTRY and at a higher rate compared with efavirenz) Trial A4001026 (96 Weeks)

Body System/ Adverse Event SELZENTRY 300 mg Twice Daily + Zidovudine/ Lamivudine
(N = 360)
%
Efavirenz 600 mg Once Daily + Zidovudine/ Lamivudine
(N = 361)
%
Blood and Lymphatic System Disorders
  Anemias NEC 8 5
  Neutropenias 4 3
Ear and Labyrinth Disorders
  Ear disorders NEC 3 2
Gastrointestinal Disorders
  Flatulence, bloating, and distention 10 7
  Gastrointestinal atonic and hypomotility disorders NEC 9 5
  Gastrointestinal signs and symptoms NEC 3 2
General Disorders and Administration Site Conditions
  Body temperature perception 3 1
Infections and Infestations
  Bronchitis 13 9
  Herpes infection 7 6
  Upper respiratory tract infection 32 30
  Bacterial infections NEC 6 3
  Herpes zoster/varicella 5 4
  Lower respiratory tract and lung infections 3 2
  Neisseria infections 3 0
  Tinea infections 4 3
  Viral infections NEC 3 2
Musculoskeletal and Connective Tissue Disorders
  Joint-related signs and symptoms 6 5
Nervous System Disorders
  Memory loss (excluding dementia) Paresthesias and dysesthesias 3 4 1 3
Renal and Urinary Disorders
  Bladder and urethral symptoms 4 3
Reproductive System and Breast Disorders
  Erection and ejaculation conditions and disorders 3 2
Respiratory, Thoracic, and Mediastinal Disorders
  Upper respiratory tract signs and symptoms 9 5
Skin and Subcutaneous Disorders
  Acnes 3 2
  Alopecias 2 1
  Lipodystrophies 4 3
  Nail and nail bed conditions (excluding infections and infestations) 6 2

Laboratory Abnormalities

Table 6: Maximum Shift in Laboratory Test Values (Without Regard to Baseline) Incidence ≥ 2% of Grade 3-4 Abnormalities (ACTG Criteria) Trial A4001026 (96 Weeks)

Laboratory Parameter
Preferred Term
Limit SELZENTRY 300 mg Twice Daily + Zidovudine/ Lamivudine
(N = 353)a %
Efavirenz 600 mg Once Daily+ Zidovudine/ Lamivudine
(N = 350)a %
Aspartate aminotransferase > 5.0 x ULN 4 4
Alanine aminotransferase > 5.0 x ULN 3.9 4
Creatine kinase 3.9 4.8
Amylase > 2.0 x ULN 4.3 6
Absolute neutrophil count < 750/mm³ 5.7 4.9
Hemoglobin < 7.0 g/dL 2.9 2.3
aN = Total number of subjects evaluable for laboratory abnormalities.
ULN=upper limit of normal.

Percentages based on total subjects evaluated for each laboratory parameter. If the same subject in a given treatment group had > 1 occurrence of the same abnormality, only the most severe is counted.

Less Common Adverse Events in Clinical Trials

The following adverse events occurred in < 2% of subjects treated with SELZENTRY. These events have been included because of their seriousness and either increased frequency on SELZENTRY or are potential risks due to the mechanism of action. Events attributed to the patient's underlying HIV-1 infection are not listed.

Blood and Lymphatic System: Marrow depression and hypoplastic anemia.

Cardiac Disorders: Unstable angina, acute cardiac failure, coronary artery disease, coronary artery occlusion, myocardial infarction, myocardial ischemia.

Hepatobiliary Disorders: Hepatic cirrhosis, hepatic failure, cholestatic jaundice, portal vein thrombosis, hypertransaminasemia, jaundice.

Infections and Infestations: Endocarditis, infective myositis, viral meningitis, pneumonia, treponema infections, septic shock, Clostridium difficile colitis, meningitis.

Musculoskeletal and Connective Tissue Disorders: Myositis, osteonecrosis, rhabdomyolysis, blood CK increased.

Neoplasms Benign, Malignant, and Unspecified (Including Cysts and Polyps): Abdominal neoplasm, anal cancer, basal cell carcinoma, Bowen's disease, cholangiocarcinoma, diffuse large B-cell lymphoma, lymphoma, metastases to liver, esophageal carcinoma, nasopharyngeal carcinoma, squamous cell carcinoma, squamous cell carcinoma of skin, tongue neoplasm (malignant stage unspecified), anaplastic large cell lymphomas T-and null-cell types, bile duct neoplasms malignant, endocrine neoplasms malignant and unspecified.

Nervous System Disorders: Cerebrovascular accident, convulsions and epilepsy, tremor (excluding congenital), facial palsy, hemianopia, loss of consciousness, visual field defect.

Postmarketing Experience

The following events have been identified during post-approval use of SELZENTRY and are not listed above. Because these reactions are reported voluntarily from a population of unknown size, it is not possible to estimate their frequency or establish a causal relationship to exposure to SELZENTRY.

Skin and Subcutaneous Tissue Disorders

Stevens-Johnson syndrome (SJS), drug rash with eosinophilia and systemic symptoms (DRESS), toxic epidermal necrolysis (TEN).

Read the Selzentry (maraviroc) Side Effects Center for a complete guide to possible side effects

DRUG INTERACTIONS

Effect Of Concomitant Drugs On The Pharmacokinetics Of Maraviroc

Maraviroc is a substrate of CYP3A and P-glycoprotein (P-gp) and hence its pharmacokinetics are likely to be modulated by inhibitors and inducers of these enzymes/transporters. Therefore, a dose adjustment may be required when maraviroc is coadministered with those drugs [see DOSAGE AND ADMINISTRATION].

Concomitant use of maraviroc and St. John's wort (Hypericum perforatum) or products containing St. John's wort is not recommended. Coadministration of maraviroc with St. John's wort is expected to substantially decrease maraviroc concentrations and may result in suboptimal levels of maraviroc and lead to loss of virologic response and possible resistance to maraviroc.

For additional drug interaction information, see CLINICAL PHARMACOLOGY.

Read the Selzentry Drug Interactions Center for a complete guide to possible interactions

Last reviewed on RxList: 4/11/2014
This monograph has been modified to include the generic and brand name in many instances.

A A A

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


WebMD Daily

Get breaking medical news.

advertisement
advertisement
Use Pill Finder Find it Now See Interactions

Pill Identifier on RxList

  • quick, easy,
    pill identification

Find a Local Pharmacy

  • including 24 hour, pharmacies

Interaction Checker

  • Check potential drug interactions
Search the Medical Dictionary for Health Definitions & Medical Abbreviations